Document:

EX-10.16

 Exhibit 10.16 

AMENDMENT NO. 1 TO LICENSE AGREEMENT 

This Amendment No. 1 (this “Amendment”), effective June 15, 2014 (the “Effective Date”), is to the
License Agreement, dated as of January 29, 2014 (the “Agreement”), by and between Trellis Bioscience LLC, a Delaware limited liability company having a place of business at 2-B Corporate Drive, South San Francisco, CA 94080
(“Trellis”), and ContraFect Corporation, a Delaware corporation having its principal place of business at 28 Wells Avenue, 3rd Floor, Yonkers, New York 10701
(“ContraFect”). Trellis and ContraFect are collectively referred to herein as the “Parties”. 
 RECITALS

 WHEREAS, Trellis and ContraFect entered into the Agreement on January 29, 2014; 

WHEREAS, Section 14.1 of the Agreement provides that binding amendments thereto shall be reduced to writing and signed by the authorized
representatives of each of the Parties; and 
 WHEREAS, the Parties desire to amend the Agreement to clarify the form of stock to be issued
to Trellis by ContraFect pursuant to Section 6.2 of the Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals and
the mutual agreements and covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree to amend the Agreement as follows: 

AMENDMENT 
 1.
Section 6.2 of the Agreement shall be replaced in its entirety with the following language (new text is bold and underlined, deleted text is struck through): 

 

	 	“6.2	Stock. (a) Within five (5) days after the Effective Date, ContraFect shall issue to Trellis five hundred thousand Dollars ($500,000) of ContraFect’s Series C1 preferred stock pursuant to the stock purchase
agreement and related investor agreements for the Series C1 preferred stock at the lowest price per share paid for the Series C1 preferred stock (including any warrants or discounts afforded such purchasers); and (b) within no
later than the date (the “Reference Date”) that is six (6) months after the Effective Date, ContraFect shall issue to Trellis an additional five hundred thousand Dollars ($500,000) of ContraFect’s Series C1
preferred stock or the preferred stock of its most recent financing round led by a non-affiliate third party at the lowest price per share paid by its investors in such round; in each case, pursuant to a stock purchase agreement and related
agreements of the Series C1 or other preferred stock, as the case may be, on a pari passu basis with the existing investors in such financing; provided, however, that in the event that ContraFect consummates an initial public
offering (the “IPO”) of its common stock (or an initial public offering of its common stock and other derivative securities related thereto) on or prior to the Reference Date, then ContraFect shall issue five hundred thousand Dollars
($500,000) of its common stock (the “Common Stock”) to Trellis in full satisfaction of its remaining obligation under this Section 6.2. ContraFect shall issue the Common Stock to Trellis fifteen Business Days after the date that
(i) the units issued in the IPO split into their component parts and (ii) the Common Stock is separately listed for trading. The number of shares of Common Stock to be issued under this Section 6.2(a) shall be calculated by dividing
$500,000 by the ten-day average closing price per share of the Common Stock, rounded down to avoid the issuance of any fractional shares. 

For the avoidance of doubt, the “ten-day average closing price per share” means the average of the last sale prices per share
reported (or if no last sale prices are reported, the average of the bid and ask prices per share) on the NASDAQ Capital Market by Bloomberg (or a substantially similar financial information reporting service, if Bloomberg is not available) for the
shares of Common Stock for each of the ten trading days ending on the date immediately prior to the date of issuance of the shares to Trellis. 

 3. Except as set forth herein, all terms and conditions of the Agreement shall remain in full
force and effect. Unless otherwise defined in this Amendment, capitalized terms used in this Amendment shall have the same meaning as set forth in the Agreement. This Amendment, together with the Agreement, constitutes the entire agreement of the
Parties with respect to the subject matter hereof, and supersedes any other agreements, promises, representations or discussions, written or oral, concerning such subject matter. 

[signature page follows] 

 IN WITNESS WHEREOF, intending to be legally bound, the Parties have executed this Amendment as of
the Effective Date by their authorized representatives. 
  

	
	TRELLIS BIOSCIENCE LLC
	
	 /s/ Stefan Ryser, Ph.D.

	Stefan Ryser, Ph.D.
	Chief Executive Officer
	
	CONTRAFECT CORPORATION
	
	 /s/ Julia P. Gregory

	Julia P. Gregory
	Chief Executive Officer

 [Signature Page to Amendment No. 1 to License Agreement]FIRST AMENDMENT TO FACILITY AGREEMENT

AND REGISTRATION RIGHTS AGREEMENT

 

 

FIRST AMENDMENT TO
FACILITY AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”), dated as of June 25, 2014, by and among
CYTOMEDIX, INC., a Delaware corporation (the “Borrower”), DEERFIELD PRIVATE DESIGN FUND II, L.P. (“DPDF”),
DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P. (“DFPDI”), DEERFIELD SPECIAL SITUATIONS FUND, L.P. (“DFSS”)
and DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. (together with DPDF, DFPDI and DFSS, collectively referred to
as the “Lenders” and together with the Borrower, the “Parties”).

 

RECITALS:

 

1. Borrower and
the Lenders have entered into that certain Facility Agreement and Registration Rights Agreement, each dated as of March 31, 2014
(as the same may be amended, modified, restated or otherwise supplemented from time to time, the “Facility Agreement”
and “Registration Rights Agreement”).

 

2. The Parties desire
to amend the Facility Agreement to extend the time for the payment of and to provide that the Yield Enhancement Payment may be
payable in shares of Common Stock of the Borrower, subject to the conditions and provisions set forth herein.

 

NOW, THEREFORE, in
consideration of the mutual agreements contained herein, the Parties agree as follows:

 

1. Defined Terms.
Capitalized terms used herein which are defined in the Facility Agreement, unless otherwise defined herein, shall have the meanings
ascribed to them in the Facility Agreement and the Registration Rights Agreement. The Recitals to this Amendment are incorporated
herein in their entirety by this reference thereto.

 

2. Amendments
to Facility Agreement.

 

a. The definition
of “Yield Enhancement Payment” in Section 1.1 of the Facility Agreement is amended in its entirety to read as follows:

 

“Yield
Enhancement Payment” means an amount equal to three percent (3%) of the outstanding principal amount of the Notes payable
by the issuance to the Lenders of duly authorized shares of Common Stock of the Borrower valued at the Yield Enhancement Price.

 

b. Section 1.1 of
the Facility Agreement is amended to add thereto the following additional defined terms:

 

    	 

    	 

    

 

“Freely Tradable Date”
means the earlier of (i) the date on which the Registration Statement (as defined in the Registration Rights Agreement) covering
all of the Yield Enhancement Shares is declared effective or (ii) the first date that all of the Yield Enhancement Shares are eligible
for resale by the Lenders that are not affiliates (as defined in Rule 144(a)(1) under the Securities Act) of the Borrower without
restriction and without the need for registration under any applicable federal or state securities laws.

 

“Freely Tradable Price”
means the Volume Weighted Average Price (as defined in Section 2.9(e)) for the Borrower’s Common Stock for the five (5) consecutive
Trading Day period beginning on the Trading Day immediately following the Freely Tradable Date.

 

“First Amendment to Facility
Agreement” means the First Amendment to Facility Agreement and Registration Rights Agreement dated as of June 25, 2014
between Borrower and Lenders.

 

“Yield Enhancement Filing Date”
means the date on which the Yield Enhancement Registration Statement is filed with the Securities and Exchange Commission.

 

“Yield Enhancement Payment
Date” shall have the meaning provided in Section 2.3(e).

 

“Yield Enhancement Price”
means the lesser of (i) the Volume Weighted Average Price (as defined in Section 2.9(e)) for the Borrower’s Common Stock
for the five (5) consecutive Trading Day period prior to the Yield Enhancement Payment Date (as defined in Section 2.3(e) below)
or (ii) the closing bid price for the Borrower’s Common Stock as of the last Trading Day prior to the Yield Enhancement Payment
Date on the principal securities exchange, trading market or quotation system (including the OTC Markets) on which the Borrower’s
Common Stock is listed, traded or quoted, provided, however, that, in the case of clause (ii), such price shall be no less than
93% of the last closing price for the Company’s Common Stock during regular trading hours on such date.

 

“Yield Enhancement Registration
Statement” means a Registration Statement (as defined in the Registration Rights Agreement)covering the resale of the
Yield Enhancement Shares.

 

“Yield Enhancement Shares”
means the shares of the Borrower’s Common Stock issuable to the Lenders pursuant to Section 2.3(e).

  

c. Section 2.3(e)
of the Facility Agreement is hereby amended in its entirety to read as follows:

 

    	 

    	 

    

 

“ On
July 9, 2014 (the “Yield Enhancement Payment Date”), the Borrower shall make a Yield Enhancement Payment to
the Lenders in accordance with the respective allocations set forth on Schedule 1 hereto. In the event that (i) the Freely Tradable
Date does not occur within twenty (20) Trading Days following the Yield Enhancement Filing Date and (ii) the Freely Tradable Price
is less than the Yield Enhancement Price (appropriately reflecting any stock splits, stock combinations, recapitalizations or other
similar events), then the Borrower shall make a cash payment to the Lenders (in accordance with the respective allocations set
forth on Schedule 1 hereto) within seven (7) Business Dates following the Freely Tradable date in an amount equal to product of
the number of Yield Enhancement Shares multiplied by the difference between (x) the Yield Enhancement Price and (y) the Freely
Tradable Price. The Borrower agrees that no later than two (2) Trading Days following the Freely Tradable Date (subject to prior
delivery by the Lenders to the Borrower or its transfer agent of the certificates representing the Yield Enhancement Shares) it
shall deliver or cause to be delivered to the Lenders certificates representing such shares that are free from all restrictive
or other legends, or, at the option of the Lenders, provided the Borrower’s transfer agent is participating in the DTC Fast
Automated Securities Transfer (“FAST”) program, the Borrower shall cause its transfer agent to electronically transmit
such shares by crediting the account of the Lenders’ prime broker with DTC through its Deposit Withdrawal Agent Commission
(DWAC) system during such two (2) Trading Day period.

 

d. Schedule 1 to the
Facility Agreement is hereby deleted in its entirety and schedule 1 attached hereto is inserted in substitution therefor.

 

 

3. Amendments
to the Registration Rights Agreement.

 

a. The definition
of “Facility Agreement” in the Registration Rights Agreement is hereby deleted in its entirety and the following is
inserted in substitution thereof:

 

“Facility Agreement”
means the Facility Agreement between the parties hereto, dated as of March 31, 2014, as amended by the First Amendment to Facility
Agreement and Registration Rights Agreement, dated as of June 25, 2014, as amended, modified, restated or supplemented from time
to time.

 

b. The date of delivery
of the Yield Enhancement Shares shall be deemed an “Issuance Date” under the Registration Rights Agreement.

 

c. The definition
of “Filing Deadline” in the Registration Rights Agreement is hereby deleted in its entirety and the following is inserted
in substitution thereof:

 

“Filing
Deadline” for each Registration Statement required to be filed hereunder other than Section 2(a)(ii), shall mean a date
that is fifteen (15) calendar days following the applicable Issuance Date, and, in the case of Section 2(a)(ii), shall mean the
Additional Filing Deadline, provided, however, that the first Filing Date shall be not be required to be prior to July 10, 2014,
provided that the Registration Statement required to be filed on or prior to such date include all Registrable Securities issued
prior to such date and that the failure to file such Registration Statement by such date shall constitute and Event of Default
under the Facility Agreement regardless of any cure period set forth therein.

 

    	 

    	 

    

 

4. Representations
and Warranties. Borrower hereby represents and warrants to Lenders as follows:

 

a. As of the date
hereof, the representations and warranties of Borrower contained in the Loan Documents are (i) in the case of representations and
warranties qualified by “materiality,” “Material Adverse Effect” or similar language, true and correct
in all respects and (ii) in the case of all other representations and warranties, true and correct in all material respects,
in each case on and as of the date hereof, except to the extent that any such representation or warranty relates to a specific
date, in which case such representation and warranty shall be true and correct in all respects or all material respects, as applicable,
as of such earlier date;

 

b. The execution,
delivery and performance by Borrower of this Amendment (i) are within Borrower’s corporate powers, (ii) have been duly authorized
by all necessary action pursuant to its Organizational Documents, (iii) require no further action by or in respect of, or filing
with, any Government Authority, and (iv) do not violate, conflict with or cause a breach or a default under any provision of applicable
law or regulation or of Borrower’s Organizational Documents or of any agreement, judgment, injunction, order, decree or other
instrument binding upon Borrower, except to the extent such violation, conflict, breach or default would not individually or in
the aggregate reasonably be expected to have a Material Adverse Effect;

 

c. This Amendment
constitutes the valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, or similar laws relating to the enforcement of creditor’s
rights generally and by general equitable principles;

 

d. No Event of Default
exists; and

 

e. The Yield Enhancement
Shares have been duly authorized and when issued and delivered in accordance with the terms of the Facility Agreement, will have
been validly issued and will be fully paid and nonassessable. There are no preemptive rights or other rights to subscribe for or
to purchase, or any restriction upon the voting or transfer of any shares of Common Stock pursuant to the Borrower’s Organizational
Documents or any agreements to which the Borrower or any of its Subsidiaries is a party or by which the Borrower or any of its
Subsidiaries is bound.

 

    	 

    	 

    

 

5. No Further
Amendments; Ratification of Liability. Except as amended hereby, the Facility Agreement and each of the other Loan Documents
shall remain in full force and effect in accordance with their respective terms. Borrower as debtor, grantor, pledgor, guarantor
or assignor, or in any similar capacity in which it has granted Liens or acted as an accommodation party or guarantor, as the case
may be, hereby ratifies, confirms and reaffirms its liabilities, its payment and performance obligations (contingent or otherwise)
and its agreements under the Facility Agreement and the other Loan Documents, all as amended by this Amendment, and the liens and
security interests granted, created and perfected thereby. The Lenders’ agreement to the terms of this Amendment or any other
amendment of the Facility Agreement or any other Loan Document shall not be deemed to establish or create a custom or course of
dealing among Borrower, Lenders, assignees, or any of them. This Amendment, together with the other Loan Documents, contains the
entire agreement among Borrower and Lenders contemplated by this Amendment.

 

6. Incorporation
by Reference. The provisions of Article 5 of the Facility Agreement are incorporated herein by reference mutatis mutandis.

 

7. Expenses.
.. The Borrower shall reimburse the Lenders for their reasonable and documented out-of-pocket expenses, including the reasonable
and documented out-of-pocket legal fees and costs, incurred in connection with the documentation of, and the consummation of the
transactions contemplated by, this Amendment.

 

[Remainder of Page Intentionally Left
Blank, signature page follows]

 

    	 

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Amendment as of the date set forth above.

 

	 	BORROWER:
	 	 	 
	 	CYTOMEDIX, INC.
	 	 	 
	 	By:	/s/ Martin P. Rosendale
	 	Name:	Martin P. Rosendale
	 	Title:	Chief Executive Officer
	 	 	 
	 	LENDERS:
	 	 	 
	 	DEERFIELD PRIVATE DESIGN FUND II, L.P.
	 	 	 
	 	By:	Deerfield Mgmt., L.P., its General Partner
	 	By:	J.E. Flynn Capital, LLC, its General Partner
	 	 	 
	 	By:	/s/ James E. Flynn
	 	Name:	James E. Flynn
	 	Title:	General Partner
	 	 	 
	 	DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
	 	 	 
	 	By:	Deerfield Mgmt., L.P., its General Partner
	 	By:	J.E. Flynn Capital, LLC, its General Partner
	 	 	 
	 	By:	/s/ James E. Flynn
	 	Name:	James E. Flynn
	 	Title:	General Partner
	 	 	 
	 	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
	 	 	 
	 	By:	Deerfield Mgmt., L.P., General Partner
	 	By:	J.E. Flynn Capital, LLC, General Partner
	 	 	 
	 	By:	/s/James E. Flynn
	 	 	James E. Flynn, President
	 	 	 
	 	DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P..
	 	 	 
	 	By:	Deerfield Mgmt, L.P., General Partner
	 	By:	J.E. Flynn Capital, LLC, General Partner 
	 	 	 
	 	By:	/s/James E. Flynn 
	 	 	James E. Flynn, President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]